当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Max Born and Carl Bosch*
Cancer continues to be a global health challenge, necessitating the development of effective anticancer medications. Camptothecin and its derivative, topotecan, are prominent chemotherapeutic agents that have demonstrated promising efficacy against various types of cancers. This dissertation aims to comprehensively investigate the novel method of action employed by camptothecin and topotecan in combating cancer. By elucidating the molecular mechanisms and cellular targets involved, this study sheds light on the pharmacological principles underlying the therapeutic potential of these drugs. The findings from this research may contribute to the development of improved treatment strategies for cancer patients. Camptothecin and its derivative, topotecan, have emerged as promising chemotherapeutic agents with potent anticancer properties. This dissertation investigates the novel methods of action employed by camptothecin and topotecan, shedding light on their mechanisms at the molecular level. The study encompasses a comprehensive literature review, experimental data analysis, and an exploration of potential future directions for research and therapeutic applications.